Molecule.one, a Poland-based artificial intelligence (AI) drug design and molecule synthesis startup, has raised USD 4.6 million in a seed funding round led by Atmos Ventures, with the participation of various other investors.
The proceeds will be used for the company’s expansion purposes, including growing the team and opening new offices in the US and Western Europe. The company is also focused on continually adding features to its AI platform, which creates theoretical molecular pathways and enables synthesis planning.
Founded in 2016, Molecule.one operates a cloud-based computational chemistry platform that assists drug developers in accelerating the discovery process by leveraging AI to design synthesis pathways and create molecules. The company was the first startup from the Central and Eastern European region to pitch at the TechCrunch Startup Battlefield in 2019.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.